Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.

Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR.

Am Heart J. 2011 Jul;162(1):115-24.e2. doi: 10.1016/j.ahj.2011.04.006. Review.

PMID:
21742097
2.
3.
4.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

5.

Aspirin for primary prevention of cardiovascular disease events.

Nemerovski CW, Salinitri FD, Morbitzer KA, Moser LR.

Pharmacotherapy. 2012 Nov;32(11):1020-35. doi: 10.1002/phar.1127. Epub 2012 Sep 27. Review.

PMID:
23019080
6.

Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.

Helton TJ, Bavry AA, Kumbhani DJ, Duggal S, Roukoz H, Bhatt DL.

Am J Cardiovasc Drugs. 2007;7(4):289-97.

PMID:
17696569
7.
8.

[Primary prevention of cardiovascular diseases with acetylsalicylic acid].

Waltering A, Hemkens L, Florack C.

Dtsch Med Wochenschr. 2005 Dec 9;130(49):2847-52. Review. German.

PMID:
16317615
9.

[Aspirin in cardiovascular prevention: does the approach differ by gender?].

Temizhan A.

Anadolu Kardiyol Derg. 2007 Dec;7 Suppl 2:2-4. Turkish.

10.

Aspirin for the prevention of cardiovascular events in the elderly.

Mahé I, Leizorovicz A, Caulin C, Bergmann JF.

Drugs Aging. 2003;20(13):999-1010. Review.

PMID:
14561103
11.

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.

Hennekens CH, Sacks FM, Tonkin A, Jukema JW, Byington RP, Pitt B, Berry DA, Berry SM, Ford NF, Walker AJ, Natarajan K, Sheng-Lin C, Fiedorek FT, Belder R.

Arch Intern Med. 2004 Jan 12;164(1):40-4.

PMID:
14718320
12.

Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?

Krane V, Wanner C.

Am J Kidney Dis. 2005 Mar;45(3):607-9. No abstract available.

PMID:
15754285
13.

Aspirin and primary cardiovascular prevention. Uncertain balance between benefits and risks.

[No authors listed]

Prescrire Int. 2010 Nov;19(110):258-61. Review.

PMID:
21284360
14.

Aspirin in the primary prevention of cardiovascular disease.

Galloway CF, Stevenson JC.

Maturitas. 2011 Jan;68(1):3-4. doi: 10.1016/j.maturitas.2010.09.011. Epub 2010 Dec 15. No abstract available.

PMID:
21111550
15.

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE.

N Engl J Med. 2005 Mar 31;352(13):1293-304. Epub 2005 Mar 7.

16.

Clopidogrel for the prevention of atherothrombotic events.

Kongsaengdao S, Arayawichanont A.

N Engl J Med. 2006 Jul 27;355(4):419-20; author reply 420-1. No abstract available.

PMID:
16874903
17.

Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.

Steinhubl SR, Bhatt DL, Brennan DM, Montalescot G, Hankey GJ, Eikelboom JW, Berger PB, Topol EJ; CHARISMA Investigators..

Ann Intern Med. 2009 Mar 17;150(6):379-86.

PMID:
19293071
18.

Aspirin for primary prevention of cardiovascular disease in Japan.

Morimoto T, Matsui K.

Intern Med. 2007;46(15):1281. Epub 2007 Aug 2. No abstract available.

19.

Update on aspirin. People with heart disease should take aspirin; the decision is trickier for those without it.

[No authors listed]

Harv Heart Lett. 2011 Aug;21(12):3. No abstract available.

PMID:
21991607
20.

Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events.

Rodondi N, Bauer DC.

Am J Med. 2004 Oct 1;117(7):528-30. Review. No abstract available.

PMID:
15464713

Supplemental Content

Support Center